<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255045</url>
  </required_header>
  <id_info>
    <org_study_id>AVM002</org_study_id>
    <nct_id>NCT02255045</nct_id>
  </id_info>
  <brief_title>Assess of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea</brief_title>
  <official_title>Evaluation of the Effect of a Vaginal Ring With Meloxicam on Primary Dysmenorrhea in Women of Childbearing Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Andromaco S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Andromaco S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose that the sustained vaginal administration would have a better
      response with respect to pain, and a better safety profile than the oral administration of a
      non-steroidal anti-inflammatory drug.

      Assess the relief of the symptoms associated to dysmenorrhea a specific survey was elaborated
      that also included a Visual Analog Scale (VAS) to make objective and measure dysmenorrhea as
      is the case with McGill's Pain Questionnaire (MPQ).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>5 months</time_frame>
    <description>Change in primary dysmenorrhea using the VAS using a vaginal ring with meloxicam during the perimenstrual period in comparison with a placebo ring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lower efficacy dose</measure>
    <time_frame>5 months</time_frame>
    <description>Determine the minimum effective dose of the vaginal ring with meloxicam in primary dysmenorrhea using the survey and the VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative</measure>
    <time_frame>5 months</time_frame>
    <description>Assess and compare the effect of a vaginal ring with meloxicam versus the oral administration of a non-steroid antiinflammatory drug commonly used for primary dysmenorrhea during one menstrual cycle, using the survey and the VAS.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Dose 1 of vaginal ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.4 g of meloxicam in a vaginal ring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 of vaginal ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 g of meloxicam in a vaginal ring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral non-steroidal anti-inflammatory drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Potassium diclofenac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaginal ring or oral pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaginal ring or placebo oral pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>meloxicam in vaginal ring</description>
    <arm_group_label>Dose 1 of vaginal ring</arm_group_label>
    <arm_group_label>Dose 2 of vaginal ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Diclofenac</intervention_name>
    <description>oral pill</description>
    <arm_group_label>oral non-steroidal anti-inflammatory drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Regular menstrual cycles on previous 3 months (24-35 days),

          -  Primary dysmenorrhea on 3 previous months,

          -  With tubal ligation or users of condom for contraception,

          -  Hemoglobin of at least 11 g/dl,

          -  Safety blood analysis in normal levels

        Exclusion Criteria:

          -  Secondary dysmenorrhea,

          -  Users of hormonal contraceptives (2 months prior to the study) or IUDs (intrauterine
             devices) (1 month prior the study).

          -  Allergy to any anti inflammatory drug including meloxicam or diclofenac.

          -  Allergy to silicon.

          -  Pregnant or in lactation.

          -  Women with untreated or decompensated endocrine disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen Shu-Chen, QF</last_name>
    <phone>+56225948479</phone>
    <email>schen@grunenthal.cl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Chileno de Medicina Reproductiva (ICMER)</name>
      <address>
        <city>Santiago</city>
        <zip>8320165</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Retamales, Midwife</last_name>
      <phone>+5626324644</phone>
      <email>aretamales@icmer.org</email>
    </contact>
    <investigator>
      <last_name>Cristian Jesam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <results_reference>
    <citation>Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD001751. doi: 10.1002/14651858.CD001751.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD001751.</citation>
    <PMID>20091521</PMID>
  </results_reference>
  <results_reference>
    <citation>Harel Z. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. J Pediatr Adolesc Gynecol. 2004 Apr;17(2):75-9. Review.</citation>
    <PMID>15050982</PMID>
  </results_reference>
  <results_reference>
    <citation>de Mello NR, Baracat EC, Tomaz G, Bedone AJ, Camargos A, Barbosa IC, de Souza RN, Rumi DO, Martinez Alcala FO, Velasco JA, Cortes RJ. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand. 2004 Jul;83(7):667-73.</citation>
    <PMID>15225193</PMID>
  </results_reference>
  <results_reference>
    <citation>Chantler I, Mitchell D, Fuller A. The effect of three cyclo-oxygenase inhibitors on intensity of primary dysmenorrheic pain. Clin J Pain. 2008 Jan;24(1):39-44. doi: 10.1097/AJP.0b013e318156dafc.</citation>
    <PMID>18180635</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>September 14, 2015</last_update_submitted>
  <last_update_submitted_qc>September 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

